The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients-Reference-Cited by-同舟云学术

The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients

Published:2019-02-12 Issue:4 Volume:22 Page:350-358
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Shahabi Ahva¹,Shafrin Jason¹,Zhao Lauren¹,Green Sarah¹,Curtice Tammy²,Marshall Alexander²,Paul Damemarie²

Affiliation:

1. Precision Health Economics, Los Angeles, CA 90025, USA;

2. Bristol-Myers Squibb, Lawrenceville, NJ 08648, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1571498

Reference29 articles.

1. The American College of Rheumatology. Rheumatoid Arthritis Fast Facts. 2017. The American College of Rheumatology. [cited 2018 August 1]; Available from: https://www.rheumatology.org/IAm-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis

2. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014

3. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I

4. Societal cost of rheumatoid arthritis patients in the US

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and factors associated with hypertension among peoples living with HIV in East Africa, a systematic review and meta-analysis;BMC Infectious Diseases;2023-10-25

2. Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study;Rheumatology International;2022-11-05

3. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records;BioDrugs;2022-06-30

4. The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States;ACR Open Rheumatology;2021-11-18

5. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study;Advances in Therapy;2021-11-09